ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ELUTIA INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.82+0.02 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $36.05M
- P/E (TTM)
- 0.9
- Dividend yield
- –
ELUTIA INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Women's Health | $7.87M | $8.60M | $9.14M | $9.33M | $10.05M | $10.61M | $11.55M | – | – | – | – | 64.9% | -21.7% |
| Cardiovascular | $4.26M | $3.85M | $3.16M | $2.51M | $2.13M | $2.47M | $2.91M | – | – | – | – | 35.1% | +100.5% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Women's Health | – | – | – | – | – | – | – | $12.23M | $11.75M | $11.58M | $10.30M | – | – |
| Cardiovascular | – | – | – | – | – | – | – | $3.04M | $3.42M | $4.06M | $5.04M | – | – |
| Device Protection | – | – | – | – | – | – | – | $9.51M | $9.83M | $9.41M | $9.40M | – | – |
By region
From the segment and revenue-disaggregation notes of Elutia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.